Global Liver Diseases Therapeutics Market 2015-2019

About liver diseases

Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.

Technavio's analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases. Based on disease indication, the market is segmented as follows:

• Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
• Liver cirrhosis
• Liver cancer
• Hepatitis (Hepatitis A, B, and C)

This report includes a discussion of the market in the following three regions:

• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India.

Technavio's report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

• Americas
• APAC
• EMEA

Key vendors

• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck

Other prominent vendors

• AbbVie
• Achillion Pharmaceuticals
• Advinus
• Angion Biomedica
• AstraZeneca
• Bayer
• BiOrion
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celsion
• Conatus
• Digna Biotech
• Dynavax Technologies
• Eli Lilly
• Galectin Therapeutics
• Genfit
• GenKyoTex
• Isis Pharmaceuticals
• Janssen Pharmaceuticals
• Kaketsuken
• La Jolla Pharmaceutical
• LG Life Sciences
• Mitsubishi Tanabe Pharma
• Nitto Denko
• Novartis
• Onyx Pharmaceuticals
• Phenex Pharmaceuticals
• Promedior
• Promethera Biosciences
• ProMetic Life Sciences
• Raptor Pharmaceuticals
• Shenzhen Kangtai Biological Products
• TCM Biotech
• Tobira Therapeutics
• VBL Therapeutics
• Verva Pharmaceuticals
• Virobay
• Zafgen

Key market driver

• Increased prevalence of liver diseases
• For a full, detailed list, view our report

Key market challenge

• Multiple patent expiries
• For a full, detailed list, view our report

Key market trend

• Growing public awareness
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Release

Technavio Announces the Publication of its Research Report – Global Liver Diseases Therapeutics Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Liver Diseases Therapeutics Market: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck

Other Prominent Vendors in the market are: Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, and Zafgen.

Commenting on the report, an analyst from Technavio’s team said: “The early detection of infections is important in reducing disease progression. For instance, the early screening and diagnosis of hepatitis C and B infections can prevent or reduce the extent of liver damage. Various government and nongovernmental organizations have been organizing awareness campaigns, seminars, summits, and fundraising events to educate people about the diseases and therapeutic measures available.”

According to the report, a significant number of approved pharmacotherapeutic products available in the market fail to completely cure hepatitis, liver cancer, cirrhosis, and nonalcoholic fatty liver disease. In addition, most of the drugs have severe side effects such as nausea and bone marrow suppression, resulting in noncompliance among individuals with liver diseases. Apart from this, the availability of hepatitis vaccines is also low in many regions due to limited public awareness of the disease and the high cost of therapeutics. All these factors further deepen the unmet medical needs of the market, presenting vendors with an opportunity to develop therapies that have better safety and efficacy profiles than available approved drugs.

Further, the report states that patent expiries of approved drugs, such as Baraclude, have led to, and will continue to lead to, the entry of their generic forms, which are less expensive. Inadequate vaccine coverage, especially in low-income countries, also negatively affects market growth.

Companies Mentioned

F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, Zafgen.